Oct 25, 2021
Collaboration and option to license the XeriJect™ technology CHICAGO --(BUSINESS WIRE)--Oct. 25, 2021-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and
Oct 05, 2021
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are now subsidiaries of Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) CHICAGO --(BUSINESS WIRE)--Oct. 5, 2021-- Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop